Literature DB >> 1705109

Nerve growth factor prevents toxic neuropathy in mice.

S C Apfel1, R B Lipton, J C Arezzo, J A Kessler.   

Abstract

Taxol is a promising new antitumor drug with therapeutic use that is limited by a toxic sensory neuropathy. Taxol is also cytotoxic to dorsal root ganglion neurons in vitro, but this effect is prevented by cotreatment with the trophic protein, nerve growth factor. We sought to develop an animal model and then to determine whether nerve growth factor can prevent taxol neuropathy in vivo. Administration of taxol to mice resulted in a profound sensory neuropathy characterized by decreases in dorsal root ganglion content of the peptide neurotransmitter, substance P, elevated threshold to thermally induced pain, and diminished amplitude of the compound action potential in the caudal nerve. Coadministration of nerve growth factor prevented all of these signs of neurotoxicity. These findings suggest that administration of nerve growth factor may prevent certain toxic sensory neuropathies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705109     DOI: 10.1002/ana.410290115

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  39 in total

1.  The protective effect of nerve growth factor in nerve tissue cultures exposed to diphtheria toxin.

Authors:  N I Chalisova; G N Akoev; V A Pennijainen
Journal:  Neurosci Behav Physiol       Date:  1999 Jul-Aug

2.  Amelioration of experimental cisplatin and paclitaxel neuropathy with glutamate.

Authors:  F M Boyle; H R Wheeler; G M Shenfield
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Neurologic Complications of Cancer Therapy.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-11       Impact factor: 3.598

4.  Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

Authors:  Jason Kato; Yuanpei Li; Kai Xiao; Joyce S Lee; Juntao Luo; Joseph M Tuscano; Robert T O'Donnell; Kit S Lam
Journal:  Mol Pharm       Date:  2012-05-01       Impact factor: 4.939

Review 5.  Chemotherapy-induced painful neuropathy: pain-like behaviours in rodent models and their response to commonly used analgesics.

Authors:  Holly L Hopkins; Natalie A Duggett; Sarah J L Flatters
Journal:  Curr Opin Support Palliat Care       Date:  2016-06       Impact factor: 2.302

6.  CD44 Signaling Mediates High Molecular Weight Hyaluronan-Induced Antihyperalgesia.

Authors:  Luiz F Ferrari; Eugen V Khomula; Dioneia Araldi; Jon D Levine
Journal:  J Neurosci       Date:  2017-11-24       Impact factor: 6.167

7.  Nerve-growth-factor-dependent neurite outgrowth assay; a research model for chemotherapy-induced neuropathy.

Authors:  A A Geldof
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 8.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

Review 9.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 10.  Animal models of chemotherapy-evoked painful peripheral neuropathies.

Authors:  Nicolas Authier; David Balayssac; Fabien Marchand; Bing Ling; Aude Zangarelli; Juliette Descoeur; François Coudore; Emmanuel Bourinet; Alain Eschalier
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.